Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in Advanced NSCLC with FGFR Alterations
NCT05287386Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
pemigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05287386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05287386.